Compare AXTA & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXTA | RGEN |
|---|---|---|
| Founded | 1910 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paints/Coatings | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.6B |
| IPO Year | 2014 | 1995 |
| Metric | AXTA | RGEN |
|---|---|---|
| Price | $34.38 | $145.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | $35.23 | ★ $167.67 |
| AVG Volume (30 Days) | ★ 3.0M | 971.4K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 286.96 |
| EPS | ★ 0.42 | 0.15 |
| Revenue | ★ $5,117,000,000.00 | $141,236,000.00 |
| Revenue This Year | $3.60 | $14.30 |
| Revenue Next Year | $3.26 | $14.52 |
| P/E Ratio | ★ $82.68 | $968.40 |
| Revenue Growth | N/A | ★ 35.10 |
| 52 Week Low | $24.94 | $100.99 |
| 52 Week High | $35.72 | $175.77 |
| Indicator | AXTA | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 64.24 | 70.07 |
| Support Level | $33.13 | $141.44 |
| Resistance Level | $35.72 | $172.45 |
| Average True Range (ATR) | 0.97 | 6.22 |
| MACD | 0.05 | 1.41 |
| Stochastic Oscillator | 70.19 | 85.92 |
Axalta Coating Systems Ltd is a manufacturer, marketer, and distributor of high-performance coatings systems. It operates in two segments: Performance Coatings and Mobility Coatings. The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial, and the Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The majority of its revenue is generated from the Mobility Coatings segment. Geographically, the company generates maximum revenue from the Europe, Middle East and Africa (EMEA) region, followed by North America, Asia Pacific, and Latin America.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.